Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Bodin K et al. | Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4. | 2001 | J. Biol. Chem. | pmid:11514559 |
Bodin K et al. | Metabolism of 4 beta -hydroxycholesterol in humans. | 2002 | J. Biol. Chem. | pmid:12077124 |
Ngaimisi E et al. | Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment. | 2014 | J. Antimicrob. Chemother. | pmid:25096076 |
Xu Y et al. | LC-ESI-MS/MS quantification of 4β-hydroxycholesterol and cholesterol in plasma samples of limited volume. | 2013 | J Pharm Biomed Anal | pmid:23948760 |
van de Merbel NC et al. | A validated liquid chromatography-tandem mass spectrometry method for the quantitative determination of 4β-hydroxycholesterol in human plasma. | 2011 | J Pharm Biomed Anal | pmid:21507593 |
Yang Z and Rodrigues AD | Does the long plasma half-life of 4beta-hydroxycholesterol impact its utility as a cytochrome P450 3A (CYP3A) metric? | 2010 | J Clin Pharmacol | pmid:20197489 |
Pataj Z et al. | Quantification of oxysterols in human plasma and red blood cells by liquid chromatography high-resolution tandem mass spectrometry. | 2016 | J Chromatogr A | pmid:26607314 |
Lütjohann D et al. | 4beta-hydroxycholesterol as a marker of CYP3A4 inhibition in vivo - effects of itraconazole in man. | 2009 | Int J Clin Pharmacol Ther | pmid:19954708 |
Dutreix C et al. | Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin. | 2014 | Eur. J. Clin. Pharmacol. | pmid:24839948 |
Hole K et al. | Impact of genetic and nongenetic factors on interindividual variability in 4β-hydroxycholesterol concentration. | 2017 | Eur. J. Clin. Pharmacol. | pmid:27975131 |